profit from every CHF 100 of sales.
CHF 0CHF 100
Ypsomed
CHF 430.40-1.56% today
+35.1% in 1 year
1-year low CHF 267.001-year high CHF 437.20
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay CHF 25.50 for every CHF 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ypsomed sold, what it kept, and what it did with the cash.
Sales went from CHF 497 million in 2023 to CHF 731 million in 2026, with CHF 222 million of profit last year.
SalesProfit
Ypsomed vs. similar companies
Ypsomed grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Ypsomed | 25.5× · Fair price | ||
 Intuitive Surgical | 53.8× · Expensive | ||
 EssilorLuxottica Société anonyme | 36.1× · Expensive | ||
 Becton, Dickinson and | 35.4× · Expensive | ||
 Medline | 44.8× · Expensive |
AI analysis
An AI analyst reads Ypsomed's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 497 | 548 | 749 | 731 | |
| 141 | 220 | 292 | 315 | |
| 61 | 86 | 113 | 246 | |
| 137 | 162 | 191 | 326 | |
| 51 | 78 | 88 | 222 | |
| 3.82 | 5.74 | 6.41 | 16.30 | |
| 28.3% | 40.0% | 39.0% | 43.0% | |
| 12.2% | 15.7% | 15.1% | 33.7% | |
| 10.3% | 14.3% | 11.7% | 30.4% |
Balance sheet
| In millions of CHF | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 862 | 1,094 | 1,330 | 1,347 |
| Cash | 25 | 74 | 36 | 29 |
| Total debt | 157 | 256 | 367 | 261 |
| Total liabilities | 300 | 476 | 651 | 598 |
| 562 | 618 | 680 | 748 | |
| 13 | 14 | 14 | 14 | |
| 6.9% | 8.4% | 9.0% | 20.6% | |
| 9.1% | 12.7% | 12.9% | 29.7% |
Cash flow
| In millions of CHF | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 130 | 163 | 148 | 307 | |
| 169 | 195 | 277 | 323 | |
| -40 | -32 | -129 | -16 | |
| Dividends paid | 8 | 18 | 27 | 30 |
| 2 | 1 | 3 | 151 | |
| – | – | – | – |
Valuation
- 25.5×
- –
- 0.41
- 7.6×
- 7.7×
- –
- 18.0×
- -0.3%
- 3.9%
- 0.5%
Profitability
- 43.0%
- 33.7%
- 30.4%
- –
- 20.6%
- 11.2%
- –
- –
- –
- –
Growth
- +13.7%
- +62.2%
- –
- –
- +0.5%
Financial health
- 0.7×
- 0.35
- –
- 76.8×
- 1.07
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 8%of 946
Top 7%of 872
Top 44%of 563
Top 43%of 868
Bottom 39%of 986
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
13.5% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
51No pass
Philip Fisher
76Pass
Peter Lynch
98Pass
Joel Greenblatt
34No pass
Charlie Munger
62Pass
Terry Smith
52No pass
Questions about Ypsomed
Is Ypsomed a good stock to buy?
A strong, very profitable business at a fair price. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ypsomed AI analysis
What does Ypsomed do?
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. It is in Medical Instruments & Supplies, based in Burgdorf, Switzerland, with 2,025 employees.
Does Ypsomed pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 14% of its yearly profit. In 2026 it paid out CHF 30.0 million in dividends.
Is Ypsomed stock halal?
Yes. Ypsomed passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Ypsomed stock done over the past year?
Up 35.1% over the past twelve months, to CHF 430.40. It traded between CHF 267.00 and CHF 437.20, close to its high.
Who are Ypsomed's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and Medline. The peers table on this page compares their profit, growth and price with Ypsomed's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.